mRNA |
ML162 |
CTRPv2 |
pan-cancer |
AAC |
-0.09 |
0.01 |
mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.094 |
0.01 |
mRNA |
BRD-K71935468 |
CTRPv2 |
pan-cancer |
AAC |
-0.1 |
0.01 |
mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.095 |
0.01 |
mRNA |
Crizotinib |
FIMM |
pan-cancer |
AAC |
0.43 |
0.01 |
mRNA |
BIRB 0796 |
CTRPv2 |
pan-cancer |
AAC |
-0.099 |
0.01 |
mRNA |
carboplatin:UNC0638 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.098 |
0.01 |
mRNA |
EX-527 |
CTRPv2 |
pan-cancer |
AAC |
-0.1 |
0.01 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.097 |
0.01 |
mRNA |
17-AAG |
CCLE |
pan-cancer |
AAC |
0.12 |
0.01 |